Media coverage about Kindred Biosciences (NASDAQ:KIN) has trended somewhat positive recently, Accern Sentiment reports. Accern identifies positive and negative media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Kindred Biosciences earned a news sentiment score of 0.24 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 45.3220205575768 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
KIN stock traded up $0.10 during trading hours on Wednesday, reaching $8.85. 69,501 shares of the company were exchanged, compared to its average volume of 77,425. Kindred Biosciences has a 52 week low of $6.50 and a 52 week high of $9.80. The company has a market cap of $248.06, a price-to-earnings ratio of -7.20 and a beta of 0.05.
Kindred Biosciences (NASDAQ:KIN) last posted its quarterly earnings results on Thursday, March 1st. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.33) by ($0.02). analysts expect that Kindred Biosciences will post -1.5 EPS for the current fiscal year.
In related news, Director Raymond Townsend sold 2,670 shares of the company’s stock in a transaction on Friday, March 16th. The shares were sold at an average price of $9.45, for a total transaction of $25,231.50. Following the completion of the sale, the director now directly owns 25,057 shares in the company, valued at approximately $236,788.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 9,180 shares of company stock valued at $86,751 over the last quarter. 19.10% of the stock is currently owned by company insiders.
About Kindred Biosciences
Kindred Biosciences, Inc is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products.
Receive News & Ratings for Kindred Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.